NanoViricides, Inc. Reports It has Successfully Improved HIVCide Drug Candidate in Cell Culture Studies
Published: Sep 16, 2013
WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB:NNVCD) (the "Company") reports that it has successfully improved upon its previous lead anti-HIV drug candidate, based on cell culture studies. An improved broad-spectrum anti-HIV nanoviricide that inhibited two distinctly different types of HIV-1 viruses equally well has been identified. This drug candidate also exhibited a very large therapeutic index. The Company has previously reported that it is optimizing the anti-HIV drug candidate. These cell culture studies were conducted by Southern Research Institute, Frederick, MD.
Help employers find you! Check out all the jobs and post your resume.